Kodiak Sciences Inc
NASDAQ:KOD

  • LAST PRICE
    3.3000
  • TODAY'S CHANGE (%)
    -0.4400 (-11.7647%)
  • Bid / Lots
    3.2300/ 5
  • Ask / Lots
    3.3000/ 12
  • Open / Previous Close
    3.7700 / 3.7400
  • Day Range
    3.2500
    3.7700
  • 52 Week Range
    1.3700
    9.8000
  • Volume
    442,495

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 15, 2024

      Show headlines and story abstract

    • 4:01PM ET on Wednesday May 15, 2024 by PR Newswire
      Companies Mentioned: KOD

       Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.

      "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We are enrolling well in GLOW2 and remain on track to activate mid-year our next Phase 3 study DAYBREAK in wet AMD which is designed to investigate the efficacy, durability and safety of tarcocimab and KSI-501 in parallel against aflibercept. We also expect to initiate Phase 1b enrollment in June for the APEX study of KSI-101, our anti-IL-6, VEGF-trap bispecific protein, in patients with macular edema associated with inflammation."

    • 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
      Companies Mentioned: KOD
      Interest expense -- (4) Other income (expense), net (337) 222 ---------- ---------- Net loss $ (43,039) $ (70,780) ========== ========== Net loss per common share, basic and diluted $ (0.82) $ (1.35) ========== ========== Weighted-average shares of common stock outstanding used in computing net loss per common share, basic and diluted 52,510,460 52,337,603 ========== ========== Kodiak Sciences Inc. Condensed Consolidated Balance Sheet Data (in thousands) (Unaudited) March 31, December 31, 2024 2023 ------------ ------------ Cash and cash equivalents $ 245,919 $ 285,507 Working capital $ 226,657 $ 247,580 Total assets $ 434,759 $ 479,372 Accumulated deficit $(1,195,570) $(1,152,531) Total stockholders' equity $ 241,189 $ 265,781

    • 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
      Companies Mentioned: KOD
      Interest expense -- (4) Other income (expense), net (337) 222 ---------- ---------- Net loss $ (43,039) $ (70,780) ========== ========== Net loss per common share, basic and diluted $ (0.82) $ (1.35) ========== ========== Weighted-average shares of common stock outstanding used in computing net loss per common share, basic and diluted 52,510,460 52,337,603 ========== ========== Kodiak Sciences Inc. Condensed Consolidated Balance Sheet Data (in thousands) (Unaudited) March 31, December 31, 2024 2023 ------------ ------------ Cash and cash equivalents $ 245,919 $ 285,507 Working capital $ 226,657 $ 247,580 Total assets $ 434,759 $ 479,372 Accumulated deficit $(1,195,570) $(1,152,531) Total stockholders' equity $ 241,189 $ 265,781

  • May 13, 2024

Peers Headlines